英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
interiors查看　interiors　在百度字典中的解释百度英翻中〔查看〕
interiors查看　interiors　在Google字典中的解释Google英翻中〔查看〕
interiors查看　interiors　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Tevimbra: Uses, Dosage, Side Effects, Warnings - Drugs. com
    Tevimbra uses Tevimbra is used to treat adults with: esophageal cancer as first-line treatment in combination with platinum chemotherapy for unresectable or metastatic ESCC whose tumors express PD-L1 (≥1) as a single-agent in unresectable or metastatic ESCC after prior systemic chemotherapy that did not include a PD- (L)1 inhibitor gastric
  • ESCC and GC GEJC Treatment | TEVIMBRA® (tislelizumab-jsgr)
    TEVIMBRA is a prescription medicine used to treat adults with: cancer of the tube that connects your throat to your stomach (esophageal cancer) TEVIMBRA may be used in combination with chemotherapy that contains platinum as your first treatment when your esophageal cancer: is a type called squamous cell carcinoma, and cannot be removed with surgery or has spread to other parts of the body
  • TEVIMBRA - accessdata. fda. gov
    TEVIMBRA, in combination with platinum and fluoropyrimidine-based chemotherapy, is indicated for the first-line treatment of adults with unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma (G GEJ) whose tumors express PD-L1 (≥1)
  • label - accessdata. fda. gov
    1 2 Gastric Cancer TEVIMBRA, in combination with platinum and fluoropyrimidine-based chemotherapy, is indicated for the first-line treatment of adults with unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma (G GEJ) whose tumors express PD-L1 (≥1) 2
  • Oncology Drug Reference Sheet: Tislelizumab-Jsgr - ons. org
    Tislelizumab-jsgr (Tevimbra®) is a programmed cell death protein-1 (PD-1) blocking antibody approved in the United States in 2024 for the treatment of certain esophageal and gastric cancers It is administered via IV and works by enhancing the immune system’s ability to target cancer cells
  • TEVIMBRA Approved in U. S. for First-line Treatment of Gastric . . .
    “Today’s FDA approval of TEVIMBRA for the treatment of gastric or gastroesophageal junction cancers in PD-L1 positive adult patients marks a significant step forward in our mission to deliver transformative therapies to patients with cancer,” said Mark Lanasa, M D , Ph D , Chief Medical Officer, Solid Tumors at BeiGene “This is the second U S approval for TEVIMBRA this year
  • Tevimbra Plus Chemo May Be Safe, Effective in Advanced . . .
    Frontline treatment with Tevimbra plus irinotecan, paclitaxel, oxaliplatin and 5-FU leucovorin had promising efficacy and manageable safety in gastric GEJ cancer Frontline treatment with Tevimbra plus chemotherapy showed promising efficacy and manageable safety in advanced gastric GEJ cancer
  • Tevimbra (tislelizumab): Uses, Side Effects, Dosage Reviews
    Tevimbra (tislelizumab) is an immunotherapy medication used to treat certain types of esophageal cancer and stomach cancer It works by helping your immune system fight cancer You can receive it alone or with chemotherapy The medication is given as an intravenous (IV) infusion, usually once every 2 to 6 weeks, depending on your dose Common side effects include tiredness, reduced appetite
  • FDA Approves Tislelizumab Plus Chemo for PD-L1+ Unresectable . . .
    Key Takeaways Tislelizumab-jsgr (Tevimbra) approved for first-line treatment of HER2-negative gastric or GEJ adenocarcinoma with PD-L1 expression Phase 3 RATIONALE-305 trial showed significant
  • TEVIMBRA Approved in US for 1L Treatment of Gastric and GEJ . . .
    “Today’s FDA approval of TEVIMBRA for the treatment of gastric or gastroesophageal junction cancers in PD-L1 positive adult patients marks a significant step forward in our mission to deliver transformative therapies to patients with cancer,” said Mark Lanasa, M D , Ph D , Chief Medical Officer, Solid Tumors at BeiGene “This is the second U S approval for TEVIMBRA this year





中文字典-英文字典  2005-2009